GENOTYPE BY ENVIRONMENT INTERACTIONS ACROSS THE AUSTRALIAN SUGARCANE INDUSTRY
By S.C. CHAPMAN, P.A. JACKSON, A. RATTEY
TWENTY-FOUR trials were planted over the sugarcane regions of Australia (Northern
NSW, Southern, Central and Northern Queensland, the Burdekin, Herbert and Ord river
districts) and harvested in 2000 to 2002 in plant and first ratoon crops. Each trial
comprised about 42 genotypes, randomly selected from several crosses, together with
5–6 commercial cultivars. The objective was to evaluate unselected genotypes, i.e.
genotypes representative of those routinely evaluated in the early stages of selection in
sugarcane breeding programs, and to consider the results in relation to optimising the
coordination of data usage and germplasm exchange between the regional sugarcane
breeding programs. This paper provides an initial examination of the results from this
research. Pooled analysis of variance revealed that Genotype x Environment (GxE)
interactions were important, with the relative variance component ratio of genotype
main effect to GxE being 1.77 for CCS and 1.25 for cane yield (TCH). Genotype x Site
interaction effects were greater than Genotype x Crop-years interaction effects within
and across regions, especially for TCH. The 3-way (Genotype x Site x Crop-year)
interaction effect was often substantial within and across regions, especially for CCS. A
large proportion of GxE interaction variance was retained within regions, and average
performance of genotypes within regions correlated well with average performance
across all regions. This suggests important factors driving genotype x site interactions
are sampled within any individual regions rather than being region specific. Averaged
over regions, there were relatively strong phenotypic correlations for CCS and TCH
between regions (> 0.5) in most cases. Some regions (e.g. North and Herbert) were
relatively well correlated for both CCS and TCH and could potentially benefit from
more coordinated evaluation and usage of germplasm in early stage selection trials in
the future.